Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Vepdegestrant Registration vs Phase 3 Tablets
NCT06347861Phase 1Completed
- Sponsor
- Pfizer
- Start
- Apr 2024
- Primary completion
- Jul 2024
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vepdegestrant in breast cancer, sponsored by Pfizer. Primary endpoints: Maximum Observed Concentration and Area Under the Curve From Time Zero to Extrapolated Infinite Time. Started Apr 2024; status: completed.
02
Drugs
vepdegestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06347861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06347861.